Objective: Nonalcoholic fatty liver disease (NAFLD) is closely associated with obesity. In this study, a North American cohort with obesity enrolled in a lifestyle modification program was examined to determine the impact of weight loss on NAFLD resolution and sarcopenia. Methods: Nondiabetic individuals with World Health Organization Class II/III obesity enrolled in a 6-month weight loss intervention were included. Steatosis was measured using computed tomography (CT)-derived liver:spleen attenuation ratio. Body composition was assessed using dual X-ray absorptiometry, air-displacement plethysmography, and CT anthropometry. Results: At baseline, participants with NAFLD had greater visceral adipose tissue (VAT) but similar skeletal muscle area compared to those without NAFLD. After intervention, weight loss was similar in the two groups, but participants with NAFLD lost more VAT than those without NAFLD (238. , P 5 0.039). Conclusions: In a Western cohort with obesity, NAFLD was not associated with sarcopenia. After lifestyle modification, there was a differential impact on NAFLD resolution, with twofold greater VAT loss in participants who resolved NAFLD compared with those with persistent NAFLD despite similar weight loss Obesity (2017) 00, 00-00.
Introduction
With the growing epidemic of obesity and metabolic syndrome, nonalcoholic fatty liver disease (NAFLD) has become the leading etiology of chronic liver disease worldwide (1) . Regional distribution of lean and fat mass may influence the development of NAFLD. Previous studies have assessed the impact of abdominal adiposity in NAFLD, but both negative and positive associations with visceral and subcutaneous adiposity have been reported (2) (3) (4) (5) (6) (7) . Decreased muscle mass, termed sarcopenia, was recently identified as a risk factor for NAFLD in Korean populations, and this effect was independent of insulin sensitivity or obesity (8, 9) . Although studies of US populations have described associations between sarcopenia and obesity-related insulin resistance (10), only one has described decreased muscle mass in participants with NAFLD (11) .
Lifestyle modification targeting weight loss is currently the most effective therapy for NAFLD. However, the relationship between quantity of weight loss and clinical benefit remains unclear. Early studies have suggested that weight loss of 7% to 10% (12) (13) (14) (15) was associated with histologic improvements in steatosis and inflammation, while more recent work has shown that as little as 5% weight loss may result in regression of fibrosis (16) . Furthermore, exercisebased interventions in NAFLD reduce intrahepatic triglyceride content independent of weight change (17, 18) . These disparate findings raise the questions of whether individuals with obesity in Western populations with NAFLD also have sarcopenia and whether weight loss interventions in these patients with NAFLD differentially impact lean and adipose tissue compartments.
To address this gap in knowledge, we analyzed a cohort of individuals with severe obesity enrolled in a weight loss interventional trial to assess the relationship between body composition and NAFLD. The aims of our study were to determine whether NAFLD is associated with sarcopenia in individuals with obesity and whether weight loss interventions differentially affect total and regional skeletal muscle and adipose tissue mass in participants with and without NAFLD. We report that in a Western population with severe obesity, the presence of NAFLD was associated with higher visceral adipose tissue (VAT) mass but not with sarcopenia. Furthermore, after the intensive lifestyle intervention program, loss of VAT was greater in individuals with NAFLD than those without NAFLD, and participants who had resolution of NAFLD lost more VAT than those participants in whom NAFLD persisted despite similar total weight loss.
Methods

Study design and participants
This study was performed in a cohort of participants previously enrolled in a clinical trial of weight loss interventions for severe obesity (RENEW, ClinicalTrials.gov trial registration identifier: NCT00712127) (19) . The Institutional Review Board at the University of Pittsburgh approved the study, and all participants provided written consent prior to participation. From February 2007 to March 2009, men and women between 30 and 55 years of age were enrolled in a single-blind randomized control trial comparing a dietary weight loss intervention to multimodal weight loss treatment with diet and physical activity. Inclusion criteria included World Health Organization Class II or III obesity (defined as BMI 35 kg/ m 2 ), ability to walk without assistance, and ability to obtain medical clearance for dietary and physical activity interventions. Exclusion criteria included history of coronary artery disease, diagnosis of cancer within 5 years of enrollment, prior bariatric surgery, prior participation in a weight loss program within 1 year of enrollment, history of diabetes mellitus, uncontrolled hypertension, and pregnancy within 6 months of enrollment. Participants with liver enzyme elevations more than 30% above the upper limit of normal laboratory ranges were excluded.
The details of the dietary and physical activity interventions have been previously described (19) . All clinical, radiographic, laboratory, and anthropometric measurements described below were obtained at baseline in a cohort of 129 participants. A subset (n 5 112) underwent measurements both at baseline and after 6 months of intervention.
Determination of NAFLD
Hepatic steatosis was evaluated with hepatic and splenic attenuation data from unenhanced abdominal computed tomography (CT) scans as previously described (19, 20) . Multiple studies have demonstrated that CT-derived indices of liver and spleen attenuation are highly sensitive for identification of moderate steatosis (21) (22) (23) . In particular, liver:spleen attenuation ratio (L/S ratio) strongly correlates with both histologic quantification of steatosis and intrahepatic triglyceride content (24) . As an L/S ratio <1.1 exhibits more than 80% accuracy for identification of 30% or more macrovesicular steatosis, NAFLD was defined as an L/S ratio <1.1.
Assessment of body composition
Whole-body fat-free mass (FFM) and fat mass (FM) were measured using either dual X-ray absorptiometry or air-displacement plethysmography in participants exceeding the weight capacity of the scanner (136 kg) (19) . Unenhanced abdominal CT scans were obtained at baseline and at 6 months to quantify VAT cross-sectional area and abdominal subcutaneous adipose area at the L4/L5 intervertebral level (19, 20) . Unenhanced CT was also used to measure midthigh skeletal muscle and a subcutaneous cross-sectional area as previously described (19, 20) .
Demographic and clinical evaluation
Participant race and ethanol use were self-reported. A detailed assessment of ethanol use was performed as previously described (19, 25) . Participants underwent measurements of height and weight to calculate BMI. Systolic and diastolic blood pressures were measured using an automated sphygmomanometer. Use of tobacco, antihypertensive agents, and lipid-lowering medications was selfreported. Clinical laboratory parameters were assessed in serum obtained from participants after a 12-hour fast. These parameters included aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, creatinine, cholesterol (total, very-lowdensity lipoprotein [ 
Adipokine and cytokine measurement
Whole blood specimens were previously collected as part of the RENEW trial. Serum was isolated by centrifugation, aliquoted, and immediately stored at 2808C for future use. Serum levels of interleukin 6 (IL-6), C-reactive protein (CRP), adiponectin, and leptin were previously measured as part of other trials (26, 27) .
Statistical analysis
Statistical analysis was performed with Stata version 13.0 (StataCorp., Boston, Massachusetts) and GraphPad Prism version 6.0 (GraphPad Software, Inc., La Jolla, California). Categorical variables were reported as absolute frequencies and percentages, and continuous variables were reported as means and 95% confidence intervals. Categorical variables were compared between groups using Fisher's exact test. Baseline values of continuous variables were compared between groups using Welch's t test. Two-way repeated measures analysis of variance (ANOVA) was used to compare postintervention changes between groups. Post hoc paired t tests were performed to assess within-group (time) differences, and unpaired t tests were used to determine differences between group differences. Holm-Sidak methods were applied to correct for multiple comparisons. P <0.05 was considered statistically significant.
Results
Clinical and demographic features of patients
Among 129 participants, 11.6% were male, and there were more men with NAFLD than without ( Table 1 ). There were no differences in age, ethnic distribution, antihypertensive medication use, lipidlowering medication use, or tobacco use between individuals with and without NAFLD. The mean BMI of the study cohort was 43.5 (42.6-44.5), and participants with NAFLD had significantly higher BMI and waist circumference than individuals without NAFLD. There were no differences in systolic or diastolic blood pressures in participants with and without NAFLD. Participants with NAFLD exhibited greater metabolic dysfunction, as fasting glucose, insulin, and homeostasis model assessment of insulin resistance were higher in participants with steatosis; HDL was lower, while LDL, VLDL, and triglycerides were higher in participants with NAFLD. AST and ALT levels were mildly elevated in the NAFLD cohort, but fasting levels of CRP, IL-6, leptin, and adiponectin did not differ between groups (Table 1) .
NAFLD is associated with higher VAT mass but not sarcopenia Individuals with NAFLD had higher absolute FM and FFM than those without NAFLD, but percent FM and FFM were similar between groups (Table 2) . Cross-sectional midthigh skeletal muscle area was elevated in NAFLD, but both midthigh and abdominal subcutaneous depots were not significantly different in patients with and without NAFLD. Abdominal VAT cross-sectional area was markedly higher in participants with NAFLD. Skeletal muscle mass, as assessed by CT, dual X-ray absorptiometry, and plethysmography, was similar in patients with and without NAFLD. However, participants with NAFLD exhibited a body composition phenotype notable for greater visceral adiposity. Because body composition is dependent on gender and our study cohort was predominately female, we re-analyzed body composition differences after excluding male participants, and our findings on body composition were qualitatively unchanged (data not shown).
Weight loss intervention reduces adipose tissue and improves hepatic insulin resistance in individuals with NAFLD
A subset of 112 participants underwent a 6-month structured weight loss intervention consisting of either dietary modification alone (DO) or with physical activity (DO1PA). Fifty-two participants (46.0%) met imaging criteria for NAFLD. There were no differences in age and ethnic distribution between individuals with and without NAFLD undergoing weight loss intervention; however, there were more men in the NAFLD cohort (Table 3 ). There was no difference in prescribed treatment regimens between groups, as similar proportions of participants with and without NAFLD were randomized to the DO and DO1PA arms (P 5 1.000); hence, the effect of weight loss modality would be similarly distributed between groups. All values reported as means and 95% confidence intervals unless otherwise specified. Post hoc paired t tests performed to assess within-group (time) differences, and unpaired t tests used to determine differences between group differences (NAFLD vs. no NAFLD). Holm-Sidak methods applied to correct for multiple comparisons. FFM, fat-free mass; FM, fat mass; SC, subcutaneous. Participants with NAFLD lost more weight after 6 months of therapy, but there were no statistically significant differences in BMI change between groups ( ; P 5 0.017 for time 3 group interaction). Together, these findings suggest that weight loss interventions lead to different depot-specific responses depending on whether NAFLD is present. Furthermore, VAT is preferentially affected by weight loss intervention in participants with NAFLD.
Changes in metabolic and inflammatory markers after weight loss intervention
Participants with NAFLD experienced greater postintervention declines in serum transaminases and fasting serum glucose levels ( Table 4) . As intrahepatic fat contributes to hepatic insulin resistance as well as hepatocellular injury, improvements in fasting glucose and transaminases may be related to greater reductions in intrahepatic fat after weight loss in NAFLD. Serum leptin, adiponectin, and CRP levels decreased similarly in patients with and without NAFLD after weight loss, but lipid profiles were not significantly improved in either cohort. Interestingly, postintervention IL-6 levels increased in patients without NAFLD but remained unchanged in patients with NAFLD; as visceral fat is an important source of IL-6, differences in IL-6 change may be influenced by VAT responses to weight loss.
These findings demonstrate that individuals with NAFLD experience greater postintervention reductions in hepatic insulin resistance, hepatocellular injury, and IL-6 secretion that those without NAFLD.
Reduction of VAT mass is associated with resolution of NAFLD
We next assessed the effects of weight loss on body composition in NAFLD subjects to determine whether postintervention changes were associated with resolution of NAFLD, which was defined as a postintervention L/S ratio 1.1. Among 52 subjects with NAFLD, 20 (38.4%) experienced resolution of NAFLD. There were no differences in the assignment of weight loss interventions between subjects with and without NAFLD resolution (10 [50%] resolved NAFLD subjects vs. 15 [46.9%] persistent NAFLD subjects underwent DO [P 5 1.000]), thus suggesting that weight loss modalities did not differentially influence NAFLD resolution (Table 5 ). Treatment nonresponders had greater transaminase levels and a lower L/S ratio, but all other measured metabolic markers, inflammatory adipocytokines, and body composition phenotypes were similar between groups.
Weight loss intervention was largely successful in patients with NAFLD, and both responders and nonresponders experienced similar degrees of weight loss (Table 6 ). Furthermore, similar proportions of individuals with and without treatment response lost at least 5% of their body mass; nonresponders, however, experienced smaller improvements in BMI. While postintervention changes in FFM were similar between groups, participants with NAFLD resolution experienced greater declines in FM, which was due to enhanced VAT loss. This finding was not accompanied by significant changes in metabolic and inflammatory markers; only postintervention changes in transaminase levels were significantly different between All values reported as means and 95% confidence intervals unless otherwise specified. Post hoc paired t tests used to determine within-group group (time) differences, and unpaired t tests used to determine between-group differences (NAFLD vs. no NAFLD). Holm-Sidak methods applied to correct for multiple comparisons. ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; IL-6, interleukin 6; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein.
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www.obesityjournal.org Obesity | VOLUME 00 | NUMBER 00 | MONTH 2017responders and nonresponders (Table 7) . Of all measured anthropometric, clinical, and metabolic factors, VAT loss alone was associated with NAFLD resolution after weight loss intervention.
Finally, we assessed postintervention changes in L/S ratio and found no differences between subjects with and without NAFLD resolution All values reported as means and 95% confidence intervals unless otherwise specified. ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; IL-6, interleukin 6; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein; FM, fat mass; FFM, fat-free mass.
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Discussion
In this study, we analyzed a North American cohort of individuals without diabetes and with severe obesity enrolled in a lifestyle modification interventional trial to assess the relationship between NAFLD and body composition before and after weight loss. We report three key observations. First, subjects with NAFLD did not exhibit lower muscle mass compared to those without NAFLD but had greater visceral adiposity and higher fasting blood glucose. Second, despite similar degrees of BMI reduction in response to weight loss intervention, subjects with NAFLD experienced greater improvements in VAT mass, waist circumference, hepatic insulin sensitivity, and serum transaminases than those without NAFLD. Third, the subsets of individuals with resolution of NAFLD after lifestyle modification experienced a twofold greater decrease in VAT compared to those with persistent NAFLD.
Previous work has suggested that NAFLD is associated with sarcopenia (8, 9, 11) . In an analysis of more than 4,000 Korean individuals, All values reported as means and 95% confidence intervals unless otherwise specified. Post hoc paired t tests performed to assess within-group (time) differences, and unpaired t tests were used to determine differences between group differences (NAFLD resolution vs NAFLD persistence). Holm-Sidak methods applied to correct for multiple comparisons. FFM, fat-free mass; FM, fat mass; SC, subcutaneous. All values reported as means and 95% confidence intervals unless otherwise specified. Post hoc paired t tests performed to assess within-group (time) differences, and unpaired t tests used to determine differences between group differences (NAFLD resolution vs. NAFLD persistence). ALT, alanine aminotransferase; AST, aspartate aminotransferase; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; IL-6, interleukin 6; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein.
the prevalence of NAFLD was higher in individuals with and without obesity when sarcopenia was present (9) . Similarly, the L4 paraspinal muscle cross-sectional area was lower in a cohort of North American subjects with biopsy-proven NAFLD compared to non-NAFLD controls (11) . However, in our study, multiple measures of skeletal muscle mass were similar in subjects with and without NAFLD. These discrepant results may be related, in part, to differences in assessment of steatosis, as clinical laboratory-based prediction models and liver biopsies were used to identify NAFLD in the aforementioned work, while CT-based definitions of steatosis were used in the present analysis. However, as our study included only North American individuals with severe obesity and without diabetes, our results suggest that ethnic, genetic, and environmental differences between populations may influence susceptibility to NAFLD and other metabolic disorders for a given degree of skeletal muscle loss.
In our study, visceral but not subcutaneous adipose tissue mass was associated with NAFLD. This finding is consistent with previous reports of enhanced visceral adiposity in hepatic steatosis (4), inflammation with fibrosis (6, 28) , and transaminase elevation (29) . While visceral adiposity may have only a minor influence on global insulin sensitivity (30, 31) , anatomic and metabolic features may explain its role in NAFLD development. Visceral fat has greater lipolytic activity than subcutaneous fat (32, 33) . Because subcutaneous adipose tissue depots were similar in both groups, VAT expansion may enhance hepatic FFA delivery in subjects with NAFLD. Subjects with NAFLD exhibited increased fasting glucose levels, which may be explained not only by hepatic resistance to insulinmediated suppression of gluconeogenesis, but also by increased availability of VAT-derived FFA as a substrate for gluconeogenesis. Although VAT elaborates several metabolically deleterious adipocytokines, circulating levels of these factors were similar between groups in our study.
Weight loss is the most effective therapy for NAFLD. However, the relationship between quantity of weight loss and clinical benefit remains unclear. Weight loss greater than 7% was associated with histologic improvement in steatosis, lobular inflammation, and ballooning (14) . Participants with as little as 5% weight loss had improvements in both insulin resistance and steatosis, while those who lost > 9% body weight experienced significant improvements in all components of the NAFLD activity score (12) . One recent study demonstrated a dose-response relationship between weight loss and histologic improvement; subjects with as little as 5% weight loss had nonworsening of liver fibrosis, while weight loss > 10% was associated with high rates of resolution of steatohepatitis (16) . On the other hand, a recent trial of bariatric surgery for the treatment of NAFLD demonstrated significant histologic improvements independent of weight loss (34) , and multiple exercise-based interventions for NAFLD decreased intrahepatic triglyceride content in the absence of significant weight loss (17, (35) (36) (37) . These findings highlight the need for a better understanding of factors influencing hepatic responses to weight loss interventions.
To this end, we assessed metabolic factors, adipocytokines, and body composition changes in patients with and without NAFLD after weight loss. Despite similar degrees of BMI change, subjects with NAFLD experienced greater reductions in VAT area. This was accompanied by significant improvements in AST, ALT, and hepatic insulin sensitivity as measured by fasting plasma glucose. All other metabolic parameters and body composition measures were similarly affected regardless of NAFLD status. Despite similar degrees of weight loss in patients with and without resolution of NAFLD, greater improvements in VAT area were observed in subjects with NAFLD resolution. Although responders and nonresponders alike had similar improvements in L/S ratio, responders had less steatosis at baseline. These findings indicate that VAT loss may be paramount to total weight loss for resolution of NAFLD and that there may be biologic determinants of VAT reduction for a given degree of weight loss. Of note, participants with NAFLD resolution had no disproportionate losses of lean mass or skeletal muscle, suggesting that weight loss interventions may be safe for muscle preservation.
Our study has a few limitations. First, as this was a retrospective analysis of prospectively collected data, causal relationships could not be established. Second, the study population was limited to a femalepredominant cohort with World Health Organization Class II and III obesity. Third, NAFLD was defined using L/S ratios from CT imaging; while L/S ratio is useful for quantification of steatosis, it cannot identify individuals with steatohepatitis or liver fibrosis. Finally, no serologic evaluation was performed to exclude viral hepatitis, but individuals with liver enzyme levels more than 30% above the upper limit of normal were excluded from the original RENEW study.
Conclusion
Among a cohort of nondiabetic subjects with severe obesity, NAFLD was not associated with sarcopenia but rather with greater visceral adiposity and metabolic dysfunction. Individuals with NAFLD resolution had twofold higher VAT loss compared to those without NAFLD resolution, despite similar degree of total body weight loss. Our results suggest that there are individual variations in response to weight loss in patients with obesity and NAFLD, which may have implications in the clinical management of this population.O V C 2017 The Obesity Society Obesity NAFLD Resolution with Weight Loss Rachakonda et al.
